AlphaQuest LLC Buys New Position in Omeros Co. (NASDAQ:OMER)

AlphaQuest LLC purchased a new position in Omeros Co. (NASDAQ:OMER) in the fourth quarter, Holdings Channel.com reports. The fund purchased 28,894 shares of the biopharmaceutical company’s stock, valued at approximately $285,000.

Other large investors have also added to or reduced their stakes in the company. MML Investors Services LLC lifted its position in shares of Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares during the period. State Street Corp lifted its holdings in Omeros by 0.3% in the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after buying an additional 3,839 shares during the period. HighTower Advisors LLC boosted its position in Omeros by 7.2% during the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 4,000 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Omeros by 21.2% during the 4th quarter. SG Americas Securities LLC now owns 24,361 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 4,257 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Omeros by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock worth $5,318,000 after acquiring an additional 6,839 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Friday, January 17th. D. Boral Capital reiterated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Thursday, February 20th. Finally, StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Trading Up 7.1 %

NASDAQ OMER opened at $8.42 on Friday. Omeros Co. has a 12 month low of $2.61 and a 12 month high of $13.60. The stock’s fifty day moving average price is $8.80 and its 200-day moving average price is $7.15. The stock has a market cap of $487.94 million, a P/E ratio of -3.65 and a beta of 2.03.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.